Drugs / immunoregulatory dendritic cells
immunoregulatory dendritic cells
also known as
iDC
Cell therapy targets CD40, CD80, CD86 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00445913 | Mar 2007 → Jan 2012 | type 1 diabetes mellitus | University of Pittsburgh | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | immunoregulatory dendritic cells | “We term these cells "immunoregulatory dendritic cells; iDC.” NCT00445913 ↗ |
| Known as | iDC | “The Control DC and the oligonucleotide-treated dendritic cells (iDC) are the study cell products in this proposal.” NCT00445913 ↗ |
| Action | Inhibit | “engineered ex vivo to exhibit suppressed expression of the CD40, CD80, and CD86 costimulatory molecules” PMID 16380489 ↗ Jan 2006 |
| Modality | Cell therapy | “autologous dendritic cell transfer” NCT00445913 ↗ |
| Target | CD40 | “targeting the primary transcripts of the CD40, CD80 and CD86 co-stimulatory molecules” NCT00445913 ↗ |
| Target | CD80 | “targeting the primary transcripts of the CD40, CD80 and CD86 co-stimulatory molecules” NCT00445913 ↗ |
| Target | CD86 | “targeting the primary transcripts of the CD40, CD80 and CD86 co-stimulatory molecules” NCT00445913 ↗ |